The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) is a huge mover today! About 529,457 shares traded hands. Aerie Pharmaceuticals Inc (NASDAQ:AERI) has risen 160.34% since March 3, 2016 and is uptrending. It has outperformed by 152.00% the S&P500.
The move comes after 9 months positive chart setup for the $1.21B company. It was reported on Oct, 6 by Barchart.com. We have $65.38 PT which if reached, will make NASDAQ:AERI worth $738.10 million more.
Analysts await Aerie Pharmaceuticals Inc (NASDAQ:AERI) to report earnings on November, 1. They expect $-0.73 EPS, down 5.80% or $0.04 from last year’s $-0.69 per share. After $-0.87 actual EPS reported by Aerie Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -16.09% EPS growth.
Aerie Pharmaceuticals Inc (NASDAQ:AERI) Ratings Coverage
Out of 9 analysts covering Aerie Pharmaceuticals (NASDAQ:AERI), 9 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Aerie Pharmaceuticals has been the topic of 18 analyst reports since August 7, 2015 according to StockzIntelligence Inc. RBC Capital Markets maintained the shares of AERI in a report on Wednesday, November 4 with “Outperform” rating. As per Thursday, September 17, the company rating was maintained by Stifel Nicolaus. The rating was maintained by Cantor Fitzgerald with “Buy” on Friday, August 7. The stock of Aerie Pharmaceuticals Inc (NASDAQ:AERI) earned “Buy” rating by H.C. Wainwright on Tuesday, September 20. The stock has “Buy” rating given by Needham on Thursday, September 15. Cantor Fitzgerald reinitiated Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Friday, June 3 with “Buy” rating. Raymond James initiated the stock with “Strong Buy” rating in Wednesday, September 14 report. On Thursday, September 15 the stock rating was maintained by Cantor Fitzgerald with “Buy”. RBC Capital Markets maintained Aerie Pharmaceuticals Inc (NASDAQ:AERI) on Thursday, September 15 with “Outperform” rating. JMP Securities initiated the stock with “Market Outperform” rating in Wednesday, September 9 report.
According to Zacks Investment Research, “Aerie Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It is focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s lead Dual- Action product and Triple-Action products are under developmental stages. Aerie Pharmaceuticals, Inc. is headquartered in Bedminster, New Jersey.”
Insitutional Activity: The institutional sentiment increased to 1.67 in Q2 2016. Its up 0.28, from 1.39 in 2016Q1. The ratio increased, as 11 funds sold all Aerie Pharmaceuticals Inc shares owned while 22 reduced positions. 9 funds bought stakes while 46 increased positions. They now own 26.15 million shares or 2.97% more from 25.39 million shares in 2016Q1.
Blackrock Invest Mgmt Ltd holds 93,699 shares or 0% of its portfolio. Moreover, Manchester Capital Mngmt Lc has 0% invested in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 150 shares. Alliancebernstein Lp, a New York-based fund reported 622,839 shares. Natl Bank Of New York Mellon Corp accumulated 0% or 132,146 shares. Teachers, a New York-based fund reported 38,197 shares. Endurant Cap Limited Partnership has 0.2% invested in the company for 33,400 shares. Blackrock Grp Inc Ltd last reported 7,724 shares in the company. Raymond James And Assocs last reported 52,563 shares in the company. Geode Capital Management Ltd Llc holds 0% or 185,594 shares in its portfolio. Harvey Capital Mgmt holds 0.96% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI) for 109,050 shares. Dekabank Deutsche Girozentrale has invested 0% of its portfolio in Aerie Pharmaceuticals Inc (NASDAQ:AERI). Fred Alger Management Inc owns 80,400 shares or 0.01% of their US portfolio. Bnp Paribas Arbitrage Sa accumulated 937 shares or 0% of the stock. Sectoral Asset Inc reported 88,400 shares or 0.16% of all its holdings. The Utah-based Wasatch Advsrs has invested 0% in Aerie Pharmaceuticals Inc (NASDAQ:AERI).
Insider Transactions: Since July 22, 2016, the stock had 1 buy, and 0 selling transactions for $4.38 million net activity. 250,000 shares were bought by Foresite Capital Management II – LLC, worth $4.38M.
Another recent and important Aerie Pharmaceuticals Inc (NASDAQ:AERI) news was published by Businesswire.com which published an article titled: “Aerie Pharmaceuticals to Host Investor Day on October 5, 2016” on September 16, 2016.
AERI Company Profile
Aerie Pharmaceuticals, Inc., incorporated on June 22, 2005, is a clinical-stage pharmaceutical company. The Firm is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s primary product candidates are Rhopressa and Roclatan. The Company’s product candidates are designed to lower intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.